Tevogen Bio Holdings Inc. | Micro-cap | Healthcare
$1.17
-0.85%
| Tevogen Bio Holdings Stock Comparison:
Tevogen Bio Holdings vs VertexTevogen Bio Holdings vs RegeneronTevogen Bio Holdings vs Alpha Tau MedicalTevogen Bio Holdings vs CartesianTevogen Bio Holdings vs Foghorn TherapeuticsTevogen Bio Holdings vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 0
Operating Income -53.6M
Net Income -13.7M
EPS (Diluted) -$0.07

Balance Sheet Metrics

Total Assets 3.5M
Total Liabilities 10.1M
Shareholders Equity -6.7M

Cash Flow Metrics

Operating Cash Flow -11.1M
Free Cash Flow -12.0M

Revenue & Profitability Trend

Tevogen Bio Holdings Income Statement From 2021 to 2024

Metric 2024 2023 2022 2021
Revenue 0 0 0 0
Cost of Goods Sold - - - -
Gross Profit - - - -
Operating Expenses 53.6M 2.3M 6.7M 4.6M
Operating Income -53.6M -2.3M -953.1K -4.6M
Pre-tax Income -13.7M -67.3K 4.4M -15.6M
Income Tax - - - -
Net Income -13.7M -67.3K 4.4M -15.6M
EPS (Diluted) -$0.07 $0.00 $0.04 -$0.13

Income Statement Trend

Tevogen Bio Holdings Balance Sheet From 2021 to 2024

Metric 2024 2023 2022 2021
Assets
Current Assets 2.4M 355.8K 274.4K 7.2M
Non-Current Assets 1.1M 16.7M 356.9M 485.3K
Total Assets 3.5M 17.0M 357.1M 7.7M
Liabilities
Current Liabilities 9.0M 3.0M 350.5K 667.9K
Non-Current Liabilities 1.1M 14.7M 14.7M 23.5M
Total Liabilities 10.1M 17.7M 15.1M 24.1M
Equity
Total Shareholders Equity -6.7M -695.8K 342.1M -16.5M

Balance Sheet Composition

Tevogen Bio Holdings Cash Flow Statement From 2021 to 2024

Metric 2024 2023 2022 2021
Operating Activities
Net Income -13.7M -67.3K 4.4M -15.6M
Operating Cash Flow -11.1M 853.7K 17.3M -5.5M
Investing Activities
Capital Expenditures 0 - -479.0K -109.7K
Investing Cash Flow 0 342.9M -479.0K -109.7K
Financing Activities
Dividends Paid - - - -
Financing Cash Flow 12.2M -341.7M 7.5M 12.5M
Free Cash Flow -12.0M -1.4M -215.4K -5.4M

Cash Flow Trend

Tevogen Bio Holdings Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 2.86
Price to Book -24.67
PEG Ratio 0.00

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity 205.68%
Return on Assets -578.29%

Financial Health

Current Ratio 0.35
Debt to Equity -0.62
Beta -0.67

Per Share Data

EPS (TTM) -$0.22
Book Value per Share -$0.09
Revenue per Share $0.00

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
tvgn 222.5M 2.86 -24.67 205.68% 0.00% -0.62
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Alpha Tau Medical 245.6M - 3.63 -47.95% 0.00% 21.83
Cartesian 250.0M 1.81 -12.32 1,138.25% -112.11% -0.65
Foghorn Therapeutics 272.6M - -5.07 190.26% 0.00% -0.57

Financial data is updated regularly. All figures are in the company's reporting currency.